Hyperthermia (42-450C) enhances the cytotoxic effects of radiation towards tumour cells both in vitro (Sapareto et al., 1978) and in vivo (Mittal et al., 1984) . In addition local hyperthermia shows promise for clinical use (for reviews see Arcangeli et al., 1988; Perez & Meyer, 1985) .
Localised tumour hyperthermia (LTH) also potentiates the tumour cytotoxicity of certain drugs (Englehardt, 1987) , including the electron-affinic 2-nitroimidazole radiosensitizer misonidazole (Bleehen et al., 1977) , in experimental tumours. The addition of misonidazole to LTH and X-rays can increase the local tumour control rates for this latter combination in mice (Overgaard, 1980; Wondergem et al., 1982) . Furthermore, a preliminary clinical study with the three modalities combined showed increased complete response rates in superficial neck node tumours compared to either radiotherapy alone or any pair of modalities together (Arcangeli et al., 1980) . Misonidazole is, however, unlikely to achieve optimal radiosensitization in man as a result of its dose-limiting neurotoxicity (e.g. Wasserman et al., 1979; Dische et al., 1982) , and less neurotoxic and/or more potent analogues are undergoing development (Bartelink et al., 1988) .
Pimonidazole (o-[(2-nitro-1-imidazolyl)methyl]-1-piperidine-ethanol; Ro 03-8799), is a basic, lipophilic derivative exhibiting more efficient radiosensitization than misonidazole in vitro (Smithen et al., 1980) . It was hoped that its pKa (8.7) would facilitate excretion in acidic urine and thereby reduce total-body exposure and hence toxicity (Wardman, 1979) . The basicity of this molecule also appears to result in accumulation within cultured cells and their lysosomes and also binding to purified DNA (Stratford et al., 1988; Dennis et al., 1985) . The drug also concentrates in tumours in vivo, resulting in tumour/plasma ratios in excess of 200% in mice and humans Allen et al., 1984; Roberts et al., 1986) . Similar ratios have been reported in several normal tissues as well (Williams et al., 1982; Roberts et al., 1986) . Tumour Calderwood & Dickson, 1983) . LTH can reduce blood-flow in rodent tumours (Dudar & Jain, 1984; Song, 1984; Reinhold et al., 1985) and has been shown to reduce both intracellular (Evanochko et al., 1983) and extracellular tumour pH, possibly through heat-stimulated anaerobic glycolysis and/or as a result of hyperthermia-induced disruptions in tumour blood-flow (Calderwood & Dickson, 1983; Reinhold et al., 1985) . A hyperthermia-induced drop in pH might be expected to increase tumour uptake of basic drugs such as pimonidazole from plasma (Wardman, 1982; Calderwood & Dickson, 1983) , providing drug availability is not blood-flow limited. The selection of pimonidazole for use with hyperthermia may therefore be particularly appropriate. In addition, hyperthermia has also been shown to enhance the reductive bioactivation of nitro compounds in vitro (Walton et al., 1987b; Olive, 1978) . In view of the enhanced cytotoxicity of nitroimidazole radiosensitisers with hyperthermia and the current clinical interest in radiotherapy combined with either radiosensitisers (e.g. Brown, 1986) or LTH (e.g. Overgaard, 1984) , the possibility of combining all three modalities for the treatment of human cancer is an attractive one (Herman et al., 1988 The KHT sarcoma was grown in the gastrocnemius muscle of the right hind leg as previously described (Twentyman et al., 1979) . Mice were treated bearing tumours of 11-13mm (orthodiagonal diameters) for pharmacokinetic experiments.
Drug supply and administration Pimonidazole, its N-oxide Ro 31-0313 (ac[(2-nitro-limidazolyl)methyl]-1-piperidine-ethanol 1-oxide) and the internal standard Ro 07-1902 (1-(2-nitroimidazol-1-yl)allyloxy propanol) were supplied by Roche (Welwyn Garden City, UK). Pimonidazole was supplied as the hydrochloride salt and all doses and concentrations are reported as the free base.
Drugs were administered in Hanks' balanced salt solution (HBSS, pH 7.4) at a fixed volume of 0.01 ml g-1 body weight via the tail vein. Pimonidazole was injected over 35-40s to avoid death by vascular shock (Williams et al., 1982) . Drugs were administered 5 min before LTH.
Localised tumour hyperthermia (LTH)
This was administered to unanaesthetised mice using a computer-controlled radiofrequency (RF)-waterbath heating system which produces uniform tumour heating with minimal increases in core (rectal) temperature (Walton et al., 1989b) . Approximately 2 min after drug administration mice were loaded into special perspex LTH jigs so that their shaved tumour-bearing legs were located between the RF electrodes. The LTH exposure was 43.5°C x 30 min, which is equal to a dose in equivalent minutes at 43°C (Eq 43) of 42.2min (Dunlop et al., 1984) . This hyperthermia dose and treatment did not result in tumour oedema or normal tissue toxicity (see Walton et al., 1989b) . Groups of 3-4 mice were treated at the same time. Mice were allocated to three different protocols: (1) combined RF-waterbath LTH at 43.5°C x 30 min; (2) sham tumour treatment in perspex jigs without LTH but with the tumour bearing leg placed in a waterbath at 37°C; and (3) no treatment (unrestrained controls). After LTH and sham treatment, mice were rubbed dry with tissue paper and briefly warmed under a 40W lamp to prevent post-treatment hypothermia.
Acute toxicity The effect of LTH on the acute toxicity (LDIo/7d) of pimonidazole was determined using tumour-bearing animals as described elsewhere (Walton et al., 1987a) . Mice were allocated to one of the three different protocols described above. Graded doses of 524-900 pgg-1 pimonidazole were given to groups of 4-5 mice with 3-4 doses per treatment.
Mice were observed for 7 days post-treatment. LD50/7d values and confidence limits were derived using pooled data from three experiments by probit analysis, using the Generalised Interactive Modelling Program (GLIM) of the Royal Statistical Society of London.
Sample analysis Samples were prepared and analysed as described in detail elsewhere (Walton et al., 1987a) . Briefly, whole blood was removed from anaesthetised animals and plasma obtained by centrifugation. Drugs were extracted into 10 volumes of acetonitrile containing the internal standard (Ro 07-1902) and taken to dryness before resuspension in 100 p1 of running buffer prior to HPLC analysis. After exsanguination animals were killed by cervical dislocation, and tumour and brain tissue was rapidly removed and snap-frozen on dry ice to prevent ex vivo metabolism. Tissue samples were homogenised (33% w/v) in distilled water before drug extraction and analysis as for plasma samples. All samples were handled on ice and stored at -20°C for up to 4 weeks before analysis.
Drug concentrations were assayed by reverse-phase, paired-ion, isocratic HPLC using a modified version of the method of Malcolm et al. (1983) as described elsewhere (Walton et al., 1987a Wagner, 1975) were calculated as described in detail elsewhere (White & Workman, 1980; Workman & Brown, 1981) 
Statistics
Significance levels were determined using the Student's t test.
Results
Effects of LTH on pimonidazole acute toxicity Table I summarises the effects of LTH on the acute lethality (LD50/7d) of pimonidazole in mice. LTH had no significant effect on pimonidazole toxicity compared to sham tumour treatment (P>0.5), and drug plus sham tumour treatment was no more toxic than in unrestrained controls (P>0.05). Deaths were either rapid and convulsive, occurring during or immediately after drug injection and before jig loading, or non-convulsive and occurring during the subsequent 24 h. No deaths resulted during the period of either LTH or sham tumour treatments. Subsequent pharmacokinetic studies were carried out at the previously determined maximum tolerated dose (-60% LD50/7d) in unrestrained control mice of 437 pg g-(see Walton et al., 1987a) (Gomer & Johnson, 1979) , and the dose of pimonidazole used in these LTH experiments has previously been shown to decrease mouse rectal temperature by 2-3°C for up to 1 h after administration (Walton et al., 1987a 37CC, and were consistently I°C higher than in unrestrained control mice given this dose of pimonidazole alone (Walton et al., 1987a) . (with 95% confidence limits) of 31.3 (28.9-34) min. As the error in treating these data as monoexponential was small (5.7%) they were fitted to a one-compartment model in accordance with the guidelines of Dvorchik & Vesell (1978) . Figure 2a shows that plasma drug concentrations were consistently higher in mice with sham-treated tumours compared to unrestrained control mice, with significant increases at 90, 120 and 180min (P<0.05 in each case). The elimination t1/2 were highly comparable (P>0.5) but sham tumour treatment reduced the apparent Vd by 18% compared to the value in unrestrained controls (P<0.05). Results are mean +2 s.e. for a typical LTH treatment using four mice. Similar results were obtained in repeat experiments. (Figure 2a) , and the respective elimination t1/2s were also very similar (Table II; P>0.5). In addition Vd, AUCO oo and P,, were minimally altered by LTH compared to sham tumour treatment (Table II) .
Brain pharmacokinetics. Brain pimonidazole concentrations reached a peak of around 340 ugg-1 in both unrestrained controls and mice with sham-treated tumours, though it was much broader in the latter group (Figure 2b) and LTH treated mice respectively, values in good agreement with previous work (Walton et al., 1987a (Figure 2c ).
The elimination t1/2 was 31.6min and the AUCo-180m.i was 441 Mgg-h (Table II) . Sham-treated tumours had a 2-fold lower peak concentration, the difference being highly significant at 20min (P<0.01). However, the levels became similar during the terminal elimination phase (Figure 2c) Table III shows the tumour/plasma ratios from the above data. Tumour/plasma ratios in unrestrained control mice consistently exceeded 200% after equilibration at 20min, in good agreement with other values (Williams et al., 1982; Walton et al., 1987a) . Ratios in sham-treated tumours were consistently less than those in unrestrained controls. Average ratios were stable from 10-180min and exceeded 100% after 35min but were all <175%. The overall mean ratios were significantly reduced in sham-treated tumours from 236 + 16.9 to 129+17% (mean+2s.e.; n=31 and 40 respectively; P <0.001).
LTH had even more pronounced effects on tumour drug concentrations compared to sham tumour treatment. LTH markedly reduced tumour/plasma ratios over the whole time course with significant decreases at 35, 120 and 180 min (Table III) . In addition, steady-state ratios never exceeded 100% in heated tumours and the average tumour/plasma ratio over this period was significantly reduced from 129 + 17 to 87.8+10.9% (mean +2s.e.; n=40; P<0.001).
Effects of LTH on pimonidazole N-oxidation Figure 3 shows the plasma concentrations of Ro 31-0313, the N-oxide metabolite of pimonidazole, after pimonidazole administration alone, or combined with LTH or sham tumour treatment. Peak plasma concentrations of Ro 31-0313 were increased during LTH compared to sham-treated mice, e.g. by 34% from 9.77 to 13.1 pgml-l at 20min (P<0.05). However, the plasma AUCo0180mmi was essentially unaffected. The values in the two independent experiments were 19.3 and 23.5 compared to 18.4 and 22.5 pgml -1 h for LTH and sham-treated mice respectively. Plasma Ro 31-0313 concentrations in unrestrained control mice were consistently lower than for sham tumour treated mice. This resulted in a 25% lower AUCo0 80mmi of 14.9 Mgml1 h, the values in two independent experiments being 14.6 and 16.1 Mg ml -1 h.
Tumour and brain Ro 31-0313 levels were frequently at or just above the lower limit of detection (-. 1Mgg-1). Maximum tumour Ro 31-0313 concentrations did not exceed 7,gg-1 giving a tumour/plasma ratio of 43%, while maximum brain concentrations did not exceed 3.5,ugg-I corresponding to a brain/plasma ratio of 63%. (Overgaard, 1979; Bleehen et al., 1977) (Williams et al., 1982; Walton et al., 1987a) . Sham-treated tumour pimonidazole drug concentrations were slightly less than those in unrestrained control tumours, giving nearly a 2-fold lower average tumour/plasma ratio of 129%. This reduction in pimonidazole concentrations in sham-treated tumours could have arisen through altered blood perfusion or metabolism in the tumour-bearing leg as a result of stress or direct restriction. If so, then not all handling artifacts have been removed from this system, and LTH might be more efficacious if applied after peak tumour drug levels have been attained.
Perhaps the most consistent and important effect of LTH was its ability substantially to reduce tumour concentrations of pimonidazole over the whole time course, giving a 31% lower AUCo0 80mmi in heated tumours compared to shamtreated ones. Tumour/plasma ratios were also significantly lower in locally heated tumours with a 41% decrease in the average steady-state ratio. This finding is similar to that reported for MISO and LTH (44°Cx60min; Honess et al., 1980) where nitroimidazole concentrations in heated tumours were reduced by up to 70% giving a 25% lower and a reduction of up to 65% in heated tumour/plasma ratios compared to controls. Decreased tumour/plasma ratios in heated tumours may be the result of several factors.
[Fhere is evidence that LTH can decrease or abolish tumour blood-flow (Bicher et al., 1980; Dudar & Jain, 1984; Song, 1984) . This might lead to reduced drug supply to the tumour and consequently lower tumour drug uptake. Moreover, if hyperthermia-decreased tumour pH occurs as a result of the accumulation of metabolic waste products through heatimpaired tumour blood perfusion, then LTH might not increase tumour uptake of basic drugs from the plasma because of limited drug supply.
An alternative explanation is that LTH stimulates the nitroreductive bioactivation of pimonidazole to non-UV absorbing metabolites (Schwartz & Hofheinz, 1982) , a process strongly implicated in the hypoxic cytotoxicity of 2-nitroimidazoles (Taylor & Rauth, 1978; Rauth, 1984) .
Further support for this hypothesis comes from our studies where LTH increased KHT tumour concentrations of the reduced amine metabolite of the 2-nitroimidazole benznidazole (Walton et al., 1989a) and other work where LTH (43°C x 60 min) increased concentrations of reduced adriamycin metabolites, especially aglycones, in murine tumours (Magin et al., 1980) . Adriamycin aglycone production in rat liver slices is also enhanced by elevated temperatures under anaerobic conditions in vitro (Dodion et al., 1986) . As pimonidazole is stable for at least 2h at 43.5°C in sodium phosphate buffer (pH 7.4 ) and mouse plasma (Walton et al., unpublished data) heat-enhanced spontaneous chemical degradation can be ruled out.
LTH increased peak plasma concentrations of the pimonidazole N-oxide metabolite Ro 31-0313 during heating. This may reflect an increase in oxidative metabolism and/or decreased plasma clearance of the metabolite. This finding is in marked contrast to WBH where pimonidazole Noxidation was greatly elevated in mouse plasma during and after the heating period (Walton et al., 1987a) . Previous studies with MISO have shown that LTH decreases peak plasma concentrations of the 0-demethylated metabolite of misonidazole, though the metabolite AUCs were comparable in heated and control mice (Honess et al., 1980) . In summary, LTH did not alter the acute lethality of pimonidazole in mice. It had minimal effects on plasma and brain pimonidazole pharmacokinetics, and only slightly increased plasma N-oxide concentrations. However, tumour drug concentrations were significantly decreased by LTH, possibly through heat-stimulated reductive bioactivation. These results show that LTH has a complex effect on pimonidazole tumour pharmacokinetics and metabolism. Further studies are required to elucidate the effects of hyperthermia on oxidative and reductive metabolism, particularly in view of the cytotoxic potential of the latter reaction in hypoxic cells and its possible enhancement in locally heated tumours. Combinations of LTH with hypoxiccell targeted radiosensitisers and other bioreductive drugs are likely to require further addition of radiation or appropriate drugs to eliminate the oxic cell population.
